Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Table 6
Treatment after hospital admission and durations of ICU and hospital stay in survivors and nonsurvivors who did and did not receive AIG-IV, Scotland, UK, 2009–2010*
Treatment characteristic | AIG-IV nonrecipient | AIG-IV recipient | p value |
---|---|---|---|
Treatments after hospital admission | |||
Days to AIG-IV receipt, median (IQR) | NA | 1 (1–3), n = 15 | NA |
ICU care | 35.7 (10/28) | 86.7 (13/15) | 0.001 |
Receipt of antimicrobial drugs | 100 (28/28) | 100 (15/15) | 1.00 |
No. antimicrobial drugs/patient during hospital stay, mean ± SE‡ | 3.0 ± 0.2, n = 28 | 5.3 ± 0.2, n = 15 | <0.0001 |
Surgery on day of admission | 17.9 (5/28) | 73.3 (11/15) | 0.0003 |
Surgery during hospital stay | 39.3 (11/28) | 93.3 (14/15) | 0.0006 |
Days to surgery, median (IQR) | 1 (0–2), n = 11 | 0 (0–0.33), n = 14 | 0.24 |
Vasopressors | 13.3 (2/15) | 33.3 (4/12) | 0.36 |
Mechanical ventilation |
33.3 (5/15) |
50 (7/14) |
0.36 |
Duration of ICU and hospital stay, median (IQR) | |||
Survivors’ ICU stay, d | 0, n = 22 | 4.5 (0.9–19.0), n = 10 | 0.0008 |
Nonsurvivors’ time to death, d | 1.3 (0.6–2.0), n = 6 | 4.0 (3.0–5.0), n = 5 | 0.07 |
Survivors’ hospital stay, d | 9.5 (2.0–17), n = 22 | 38 (31–42), n = 10 | 0.001 |
*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate no. patients for whom data were available. Bold indicates significant differences between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; ICU, intensive care unit; IQR, interquartile range; NA, not applicable.
1These authors contributed equally to this article.